New developments in the treatment of metastatic gastric cancer: focus on trastuzumab

Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Jeffrey S, Bekaii-Saab, Tanios S
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084304/
https://www.ncbi.nlm.nih.gov/pubmed/21552412
http://dx.doi.org/10.2147/OTT.S10188
_version_ 1782202492863381504
author Rose, Jeffrey S
Bekaii-Saab, Tanios S
author_facet Rose, Jeffrey S
Bekaii-Saab, Tanios S
author_sort Rose, Jeffrey S
collection PubMed
description Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.
format Text
id pubmed-3084304
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30843042011-05-06 New developments in the treatment of metastatic gastric cancer: focus on trastuzumab Rose, Jeffrey S Bekaii-Saab, Tanios S Onco Targets Ther Review Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer. Dove Medical Press 2011-03-24 /pmc/articles/PMC3084304/ /pubmed/21552412 http://dx.doi.org/10.2147/OTT.S10188 Text en © 2011 Rose and Bekaii-Saab, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Rose, Jeffrey S
Bekaii-Saab, Tanios S
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
title New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
title_full New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
title_fullStr New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
title_full_unstemmed New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
title_short New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
title_sort new developments in the treatment of metastatic gastric cancer: focus on trastuzumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084304/
https://www.ncbi.nlm.nih.gov/pubmed/21552412
http://dx.doi.org/10.2147/OTT.S10188
work_keys_str_mv AT rosejeffreys newdevelopmentsinthetreatmentofmetastaticgastriccancerfocusontrastuzumab
AT bekaiisaabtanioss newdevelopmentsinthetreatmentofmetastaticgastriccancerfocusontrastuzumab

Ejemplares similares